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Monitoring guidelines for methotrexate-treated
rheumatoid arthritis patients: comment on the article
by Yazici et al
To the Editor:
In a recent article, Yazici and colleagues used data
from a survey of a relatively small number of rheumatologists
to support the notion that a laboratory monitoring regimen for
methotrexate (MTX)-treated patients with rheumatoid arthri-
tis (RA) that is less intensive than that suggested by the
American College of Rheumatology (ACR) is desirable (1).
The lack of guidelines for monitoring patients receiving bio-
logic compounds (anti–tumor necrosis factor and anti–
interleukin receptor antagonist) was also noted in their report
(1). The authors go on to suggest that the guidelines for
monitoring MTX therapy need to be updated, and that guide-
lines for monitoring biologic compounds need to be drawn.
Although we strongly agree with the second statement, we feel
uncomfortable concluding, based on the data presented, that
the ACR guidelines for monitoring MTX therapy need to be
modified. Whereas these guidelines are far from being perfect,
they are still the best we have; for persons unfamiliar with the
original 1994 publication, the guidelines were derived from
data based on sound methodology (2).
In a related matter, we want to point out that data
gathered in a selected group of patients with RA (n  313),
who were followed up at less frequent intervals than those
recommended by the ACR, and who only rarely presented
abnormal liver function test abnormalities, were presented by
Yazici et al at the 2003 annual meeting of the ACR (3).
Unfortunately, these data have been quoted on the internet
(e.g., eRheumatology News) as coming from the ACR, sug-
gesting that the ACR guidelines are being “adjusted” (4). This,
we think, is quite misleading to the clinician given that the
ACR has not endorsed the conclusions presented in this
abstract.
Is it possible that we have become too complacent in
monitoring methotrexate therapy because we may not have
personally witnessed a case of clinically significant liver dis-
ease? Changing the guidelines should be a meticulously data-
driven process rather than based on the current practice
patterns of a relatively small group of rheumatologists; at the
conclusion of such a process, the guidelines may indeed be
changed. If that is the case, we will be the first to welcome such
change. Until then, we should use the guidelines as they are.
Graciela S. Alarcón, MD, MPH
University of Alabama at Birmingham
Joel Kremer, MD
The Center for Rheumatology
Albany, NY
Michael Weinblatt, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
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Thank you for the opportunity to respond to the letter
by Drs. Alarcón, Kremer, and Weinblatt. With all due respect
for the 8 rheumatologists on the Subcommittee on Hepatic
Toxicity and MTX of the ACR who developed the current
guidelines (1), the number of rheumatologists included in our
study (n  123) is 15-fold larger, representing 5% of
practicing rheumatologists in the US. These rheumatologists
provided their views concerning standard, everyday care of
patients with RA. Furthermore, the current guidelines appear
to be based on 446 patients, rather than the quoted 700 (2), 383
of whom had been the subject of 11 previously published
studies, 8 of which were continuations of 3 reports of the same
patients. This methodology may have led to a misleading total.
I also agree that the current guidelines for MTX
monitoring are the best we have, but they are also the only
guidelines available. The assumptions concerning clinically
significant liver disease rates and the risks associated with liver
biopsies (3), as well as the arbitrary choice of testing intervals
not supported by data (4), in the development of these
guidelines have already been challenged. Other investigators
have also suggested modification of the current guidelines,
with less frequent laboratory monitoring (5,6). Surely the
authors are not suggesting monitoring blood tests every 4
weeks, which would be the literal interpretation of these
guidelines.
Drs. Alarcón, Kremer, and Weinblatt also suggest that
an abstract presented at the 2003 ACR meeting about the
small number of liver function test abnormalities observed
among 313 RA patients was presented as an ACR-endorsed
statement by a commercial Web site for rheumatologists. This
was a newsreel about the abstract about MTX and liver
function test abnormalities. There was no indication of an
ACR endorsement, and I personally had no control nor any
role in the preparation of this newsreel.
Finally, it would be of interest to learn the current
prevalence of liver function test abnormalities in patients seen
by Drs. Alarcón, Kremer, and Weinblatt, to compare with data
reported by me and my colleagues, to help the rheumatology
community judge the optimal frequency of laboratory moni-
toring of patients treated with MTX.
Yusuf Yazici, MD
Brooklyn Heights Arthritis Associates
Long Island College Hospital
Brooklyn, NY
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Intravenous immunoglobulin and antiphospholipid
syndrome: comment on the article by Erkan et al
To the Editor:
We read with interest the article by Erkan et al
addressing the recent consensus on the diagnosis and treat-
ment of the catastrophic antiphospholipid syndrome (CAPS)
and focusing on the latest advances (1). In their report, Erkan
et al consider intravenous immunoglobulin (IVIG) as a ther-
apy to be used in addition to anticoagulants and steroids in
cases of life-threatening conditions, specifying that IVIG is
well tolerated but is contraindicated in patients with IgA
deficiency. However, the authors do not mention that arterial
or venous thrombotic events following IVIG infusion have
been reported (2–4).
The place of IVIG in the therapeutic arsenal for APS
still must be defined, even though IVIG has been shown to
improve pregnancy outcome in association with use of anti-
coagulants and aspirin (5). However, CAPS constitutes a very
special condition related to APS that can be difficult to
distinguish from thrombotic thrombocytopenic purpura (TTP),
as Erkan pointed out. We previously reported the case of a
42-year-old woman with idiopathic TTP whose neurologic
symptoms seriously worsened immediately after IVIG infu-
sion, making the use of IVIG questionable in the acute phase
of the disease (6). In such cases, we believe that use of IVIG
might be deleterious. Moreover, in the series of 80 patients
affected by CAPS reported by Asherson et al in 2001 (7), there
was no difference regarding recovery between patients who
had received IVIG and patients who had not. However, only 15
of 80 patients (19%) received IVIG; this small number pre-
vents drawing any conclusion.
The mechanism of IVIG-related thrombosis remains
unclear, but a rise in blood viscosity dependent on the dose
infused is suspected; this rise could last for up to 1 month (8).
In addition, IVIG could enhance platelet aggregation, activate
the coagulation cascade, as well as mediate vasospasm (9,10).
In conclusion, the safety of IVIG in the treatment of
CAPS cannot be warranted, and IVIG should be used very
cautiously given the risk of accelerating the so-called clotting
storm. In the absence of more evidence, we think that plasma
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We thank Jean et al for their comments on our recent
article. CAPS has now been researched for 12 years, and we do
believe, based on the information available on 130 docu-
mented and analyzed patients (1,2) as well as a further 100
cases now in the CAPS registry (3), that IVIG should definitely
be included among the major therapeutic options for patients
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with this unusual and often fatal syndrome. Due to the small
number of IVIG-treated patients thus far, statistical evidence
may not be available at the present time; however, we believe
that with the increasing number of reported cases and the
more frequent use of IVIG, this evidence will be forthcoming
in future analyses. Our reasons for the use of IVIG in CAPS
patients are as follows.
1. IVIG has successfully been used in both experimental
APS animal models (4) and APS patients with pregnancy
morbidities (5). The mode of action of IVIG is antiidio-
typic, directed to antiphospholipid antibodies, leading to
immunomodulation of their pathogenetic role (5).
2. Based on our analysis of the CAPS registry, in the
presence of an inadequate response to anticoagulation
and corticosteroids, either IVIG or plasma exchange
clearly improves the outcomes (3,6). However, currently
it is unknown whether the addition of plasma exchange is
superior to the addition of IVIG, and the outcomes of
patients receiving anticoagulation, corticosteroids, and
IVIG are not different from those of patients receiving
anticoagulation, corticosteroids, and plasma exchange
(3).
3. There have been a few reports of thrombosis with IVIG
when it is used at doses higher than those recommended
(0.4 gm/day per kilogram of body weight), administered
at a rate of infusion higher than that recommended, or in
the presence of other major thrombotic risk factors (7,8).
The 42-year-old patient with TTP mentioned by Jean et al
and described by Duran et al in 1994 is an excellent
example of these concerns (9). That patient had been
receiving oral contraceptives at the time of TTP diagno-
sis, received IVIG at a dose of 0.5 gm/kg of body weight,
and neurologic deterioration occurred 4 hours after the
infusion (the infusion rate is not reported).
4. Based on our experience in IVIG-treated CAPS (1–3)
and non-CAPS patients (10), we did not encounter a
single event of thromboembolism attributable to IVIG.
5. Also as noted by Jean et al, TTP and heparin-induced
thrombocytopenia share similarities with CAPS, and
IVIG has been successfully used for these conditions
(11–12).
6. Infections may play a triggering role in many CAPS
patients, and IVIG has a broad spectrum of antibacterial
and antiviral activity (13). Thus, treating CAPS patients
with IVIG may offer additional therapeutic advantages.
7. Plasma exchange can be associated with its own compli-
cations. As noted by Duran et al, the sudden rebound of
the anticardiolipin antibodies following plasma exchange
can contribute to thrombotic microangiopathy, and
plasma exchange should be used cautiously in the absence
of immunosuppressive therapy (14).
In summary, due to the low frequency of side effects
encountered with IVIG (15) in addition to the multiplicity of
therapeutic actions seen with this compound, and the fact that
all CAPS patients, in any event, are receiving full doses of
anticoagulation therapy simultaneously, IVIG should abso-
lutely be included in the therapeutic armamentarium offered to
these patients, who have a potentially life-threatening condition.
Doruk Erkan, MD
Hospital for Special Surgery
New York, NY
Ronald Asherson, MD
University of Cape Town
School of Medicine
Cape Town, South Africa
Ricard Cervera, MD, PhD
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HLA–DQA1 as a risk factor for microchimerism:
comment on the article by Artlett et al
To the Editor:
The recent article by Artlett et al (1) addresses the
topic of whether specific HLA alleles are associated with
persistent microchimerism, a potential risk factor for auto-
immune diseases, as described previously (2). Because the
results of the study by Artlett et al are described in comparison
with our previous report, I would like to clarify a few descrip-
tions that are not correct. Artlett and colleagues state that, in
contrast to our study, they did not find the HLA–DQA1*0501
allele or any other DQA1 allele to be a risk factor for fetal
microchimerism in either T lymphocytes or whole peripheral
blood from the SSc patient cohort or the controls. First, we
never tested whole peripheral blood in our study. Second,
although DQA1*0501 was more frequent among women with
fetal microchimerism within T lymphocytes, as stated in our
article, this finding was not significant when corrected by the
number of alleles tested. I am not surprised that Artlett et al
did not observe an association with the host’s genotype.
In our study, we observed that fetal microchimerism
within maternal T lymphocytes was associated with the HLA
genotype of the son (donor). Artlett et al describe no signifi-
cant association of maternal microchimerism within the T
lymphocytes of the child according to the presence of
DQA1*0501 in the mother (n  10) or of fetal microchimerism
within maternal T lymphotyes (n  27) according to the
presence of DQA1*0501 in the child. Although the latter result
contrasts with our prior report (n  29), it is difficult to draw
conclusions for a number of reasons. Perhaps the most impor-
tant reason is that different techniques were used to detect
microchimerism. The study by Artlett et al is heterogeneous
for techniques used to detect microchimerism, and it is difficult
to ascertain important variables such as the total amount of
DNA tested and the purity of sorted subsets. Furthermore,
results were combined from quantitative and nonquantitative
assays (e.g., a weaker third band was classified as the micro-
chimeric allele), and the criteria used to categorize individuals
as positive or negative were not defined. Moreover, quantita-
tive and nonquantitative techniques show different sensitivi-
ties, with, respectively, a sensitivity of 1 male cell in 100,000
female cells (3) and 10 cells in 2.4 million host cells (4).
Adding further confusion, either care was not taken in
the description of results, or the quantitative results are at
marked variance with any other literature report, because in
Patients and Methods it is stated that results were normalized
to 100,000 autologous cells, and in the Results section ranges
of 1–12 (low) and 13–1,130 (high) microchimeric cells are
reported—representing levels as high as 1% of all circulating
cells
Methods to detect and accurately quantify microchi-
merism have advanced considerably since our study in 2000.
Further studies will be necessary, in which standardized and
carefully conducted techniques are used to study larger num-
bers of individuals. A final issue we previously raised is
whether patients with autoimmune diseases who lack disease-
specific HLA molecules could be investigated for persistent
microchimerism as an alternative source of HLA disease–
associated molecules or peptides, whereas patients who have
the disease-specific HLA molecules might not have persistent
microchimerism. This is one potential explanation for the
observation by Artlett et al that DQA1*0501 was frequently
observed in patients who were negative for microchimerism,
even though juvenile idiopathic inflammatory myopathy is
frequently associated with DQA1*0501.
Nathalie C. Lambert, PhD
Institut National de la Santé
et de la Recherche Médicale Unité 639
Marseille, France
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Dosage effects of orally administered bovine type I
collagen on immune function in patients with systemic
sclerosis
To the Editor:
Type I collagen (CI), the most abundant protein in
humans, may play a pivotal role in the pathogenesis of systemic
sclerosis (SSc) (1–6). Oral tolerance studies in rodents have
shown that the dose-response curve for orally administered
antigen is bimodal, with tolerance being induced optimally
using low and high doses of antigen (7). It has been postulated
that high-dose oral antigen induces predominantly clonal
deletion of antigen-specific T cells, while low-dose oral antigen
induces regulatory T cells (8,9). Work from our institution has
demonstrated that oral administration of CI at 500 g/day in
patients with SSc induces tolerance, as characterized by signif-
icant reductions in interferon- (IFN) and interleukin-10
(IL-10) production by peripheral blood mononuclear cells
(PBMC) cultured with 1(I) and 2(I). This dosage of CI also
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effected improvement in several disease parameters, including
skin scores (modified Rodnan skin scores [MRSS]) (10),
patient assessment of disease activity (modified Health Assess-
ment Questionnaire [M-HAQ]) (11), and results of pulmonary
function tests (PFTs), including diffusing capacity for carbon
monoxide (DLCO) and forced vital capacity (FVC) (12).
Studies in humans with rheumatoid arthritis (9), as well
as in animals (13,14), suggest that the oral dosage of an
autoantigen such as collagen is pivotal in determining whether
tolerance occurs and disease activity is suppressed. In our
previous study of oral CI administration to patients with SSc,
we used high doses of collagen (500 g/day) and did not
explore the effects of lower-dose regimens (12). The purpose
of the present study was to determine whether lower doses of
oral CI (10 g/day and 100 g/day) would induce immune
tolerance to CI in patients with SSc, and/or whether a change
in clinical parameters could be effected after 5 months of
administration of CI at either or both of these dosages.
The study population consisted of 4 men and 18
women with SSc (17 white, 5 African American). Patients were
recruited from the University of Tennessee (UT) and commu-
nity rheumatology practices in Memphis and surrounding
areas. The mean  SD duration of disease in the study
population was 6.7  7.5 years (range 1 month to 30 years).
Eight patients had limited SSc and 14 had diffuse SSc. Written
consent for participation in the study was obtained from
patients in accordance with the Helsinki II declaration, and the
protocol was approved by the UT Institutional Review Board.
The study was conducted under US Food and Drug Adminis-
tration Investigational New Drug application 6575. The inclu-
sion criterion was a clinical diagnosis of limited or diffuse SSc
made by the study physician, according to the criteria of the
American College of Rheumatology (formerly, the American
Rheumatism Association) (15). Exclusion criteria were similar
to those in our previous study (12); however, treatment with
nonsteroidal antiinflammatory drugs (NSAIDs) was not al-
lowed. The rationale for the exclusion of NSAIDs was based
on work from our institution suggesting that NSAIDs may
impede the development of oral tolerance (16).
For the first 5 months, all patients received placebo
(0.1M acetic acid). Patients were then randomized to receive
CI at 10 g/day or 100 g/day for 5 months. Those who had
received the 10 g/day CI dosage for 5 months were then
crossed over to receive the 100 g/day dosage for 5 months,
and vice versa. Collagen was solubilized in 0.1M acetic acid and
aliquoted into individual-dose vials which the patients kept
refrigerated. Each morning, the patient added 1 vial of the CI
preparation to 4–6 ounces of orange juice, and this was
consumed before breakfast. Compliance was monitored by
counting the milliliters of study drug left in vials returned at
each visit. Patients were considered to have complied with the
protocol if they have consumed at least 70% of the study
medication. The mean consumption was 88.8% (range 71.2–
96.9%).
All assessments were performed at 0, 5, 10, and 15
months. The MRSS (assessed by the same trained physician
throughout) and the M-HAQ score were recorded. PFTs,
including FVC and DLCO studies, were performed by the same
technician (under the direction of a pulmonologist), using the
same equipment each time. IFN and IL-10 levels were
measured, by commercial enzyme-linked immunosorbent as-
say (ELISA; R&D Systems, Minneapolis, MN), in superna-
tants that were harvested from in vitro cultures of SSc PBMCs
and stimulated with phytohemagglutinin (PHA; 5 g/ml),
1(I) (50 g/ml), or 2(I) (50 g/ml) for 6 days. IFN and
IL-10 levels in unstimulated PBMC culture supernatants were
subtracted at each time point from the levels in supernatants
from PBMCs stimulated with PHA, 1(I) or and 2(I). Serum
levels of soluble IL-2 receptor (sIL-2R), a marker of in vivo
immune activation, were measured by ELISA (R&D Systems).
All samples were tested in duplicate.
Data were analyzed in a covariance structural model to
fit a crossover design (PROC MIXED, version 9.1; SAS
Institute, Cary, NC). Analyses were performed to determine
whether there were significant differences in the mean re-
sponses to collagen at 10 g/day versus 100 g/day, collagen at
10 g/day versus placebo, and collagen at 100 g/day versus
placebo. Results were adjusted for baseline measurements
(including MRSS, M-HAQ score, PFT results, and cytokine
levels), age, race, sex, disease duration, and type of SSc
(limited versus diffuse).
Eighteen patients received 5 months of placebo treat-
ment, 14 received at least 1 dose of oral CI, and 11 completed
the entire study. The 11 study withdrawals were due to issues
regarding compliance (n  6), traumatic Colles fracture (n 
1), intercurrent medical illnesses not related to SSc (n  2),
pregnancy (n  1 [during placebo treatment]), and allergic
reaction to collagen characterized by a skin rash (n  1). The
final sample size was similar to that in our previous study, in
which only 17 patients completed the protocol, and of these,
only 11 actually had PFTs performed (12). Despite these small
numbers, statistically significant results had been demon-
strated for immune and clinical parameters, including PFT
results, after 1 year of treatment with oral bovine CI at 500
g/day (12).
There were no significant differences in response to CI
at either 10 g/day or 100 g/day compared with placebo, with
respect to clinical parameters including MRSS, M-HAQ score,
and PFT results (FVC and DLCO). Interestingly, there was a
significant increase in IFN production in response to 2(I) by
PBMCs from patients receiving CI at 100 g/day compared
with both the placebo group (P  0.02) and the 10 g/day CI
group (P  0.01). There were no significant differences in the
IFN response to 1(I) or in the IL-10 response to 1(I) or
2(I) among the treatment groups. In addition, levels of
sIL-2R did not differ among the groups (P  0.05).
The major finding of our study was that there was no
significant response in any of the clinical parameters evaluated,
including MRSS, M-HAQ, or PFTs, to oral bovine CI admin-
istered at either 10 g/day or 100 g/day for 5 months.
Furthermore, there was no suppression of the T cell response
to CI (i.e., reduction in IFN and/or IL-10 production) and no
change in systemic immune activity. However, with the 100
g/day dosage of CI, we did note increased in vitro production
of IFN; this response was seen with 2(I) stimulation, but not
1(I) stimulation. Increased IFN production by peripheral
lymphoid cells cultured with tolerizing antigen has been asso-
ciated with induction of tolerance to some orally administered
antigens in humans and mice (17,18). Whether this enhanced
IFN production in response to 2(I) represents tolerance
induction or whether increased production of endogenous
IFN is beneficial in SSc requires further investigation. Induc-
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tion of IFN may be important because of the antifibrotic
properties of this cytokine (19).
It should be noted that our results are limited by the
small number of patients who completed the study, the wide
range of disease duration, and the probable need to administer
oral CI for longer than 5 months to observe a change in skin
scores or pulmonary function. However, our findings suggest that
low-dose CI may have some effect on cytokine profiles in SSc,
although no response in any clinical parameters was noted.








Karen D. Barrow, MS
Kenneth Warrington, MD
Grant Somes, PhD
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Recommendations regarding individuals in whom
bone densitometry should be performed: comment on
the article by van Staa et al
To the Editor:
We read with great interest the article by van Staa and
coworkers on the bone mineral density (BMD) threshold for
prediction of vertebral fractures in patients receiving oral
glucocorticoid therapy (1). Compared with non–glucocorticoid
users, glucocorticoid users appear to develop fractures at a
higher BMD. The American College of Rheumatology recom-
mends therapeutic intervention if the T score for BMD is
below 1 in a patient who has had long-term treatment with
glucocorticoids (2). The UK National Osteoporosis Society
advocates intervention at a T score threshold of 1.5 (3). With
the increasing use of bone density testing for diagnosing
osteoporosis and establishing fracture risk, inconsistencies
have arisen in the way in which bone densitometry is per-
formed and the results interpreted. As an example, T score
diagnostic thresholds for postmenopausal Caucasian women
not exposed to glucocorticoids may not apply to patients who
are receiving glucocorticoid therapy. A similar analogy could
be made in applying World Health Organization T score
criteria to men and premenopausal women.
To reduce these inconsistencies and improve interpre-
tation and reporting of BMD, the International Society for
Clinical Densitometry (ISCD) periodically convenes Position
Development Conferences (PDCs). The most recent PDC was
held in Cincinnati, Ohio, in July 2003. The ISCD is a not-for-
profit multidisciplinary professional society with a mission to
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enhance knowledge and quality of bone densitometry among
health care professionals. In addition, it provides continuing
education courses for clinicians and technicians, and it sup-
ports clinical and scientific advances in the field.
The decision on whether to initiate therapeutic inter-
vention must be made on the basis of knowledge of the
individual patient and his/her associated risk factors, not on the
basis of a numerical score. However, one of the goals of a
professional society is to standardize the understanding of the
field as much as possible based on evidence, as exemplified in
the report by van Staa et al.
The ISCD recommends BMD testing in the following
individuals: 1) women age 65 and older; 2) postmenopausal
women under age 65 with risk factors; 3) men age 70 and older;
4) adults with a fragility fracture; 5) adults with a disease or
condition associated with low bone mass or bone loss; 6) adults
taking medications associated with low bone mass or bone loss;
7) anyone being considered for pharmacologic therapy; 8)
anyone being treated, to monitor treatment effect; and 9)
anyone not receiving therapy in whom evidence of bone loss
would lead to treatment.
A complete review of all ISCD official positions is
published in the Journal of Clinical Densitometry (4). A sum-
mary of the ISCD official positions is available online at the
ISCD Web site (www.iscd.org), where there is also a viewable
and downloadable slide presentation of the positions.
Oscar S. Gluck, MD
Michael J. Maricic, MD
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Tucson, AZ
Edward S. Leib, MD
University of Vermont College of Medicine
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E. Michael Lewiecki, MD
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No justification for publication of study on
subgrouping of fibromyalgia patients: comment on the
article by Giesecke et al
To the Editor:
The diagnosis of fibromyalgia continues to be a con-
tentious and disputed issue in rheumatology. As Sherine
Gabriel puts it, citing Cohen and Quinter, “Diagnostic criteria
for fibromyalgia convey no pathophysiologic insight and . . .
have been validated via a circular argument in which the
evidence on which the construct is based is taken as proof of its
veracity” (1). Thoughtful rheumatologists have abandoned this
untenable concept.
Nonetheless, a study recently presented in Arthritis &
Rheumatism (2) even creates subgroups (!) based on pressure-
pain thresholds and psychological factors. The fact that this
makes little sense from the standpoint of evidence-based
medicine or science did not prevent it from being published.
This article ranks with the many presentations at the American
College of Rheumatology meetings in Orlando this year de-
voted to this portion of the chronic pain spectrum that serves
to delight litigators and their allies and that has made the
diagnosis an industry, with a plethora of “journals” published
by Haworth Press, but no justification for validation by publi-
cation in Arthritis & Rheumatism.
Furthermore, in an article appearing in the same issue
of Arthritis & Rheumatism in which the report by Giesecke et al
appears, Conte and colleagues rightly place the afflictions of
the children described in the pain syndromes but then, without
justification, classify their problems as fibromyalgia (3). To
quote from the ACP Observer, “A label can be counterproduc-
tive for people who are particularly susceptible to suggestion
and playing the sick role” (4).
George E. Ehrlich, MD, MACR
Philadelphia, PA
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et al. Subgrouping of fibromyalgia patients on the basis of pressure-
pain thresholds and psychological factors. Arthritis Rheum 2003;
48:2916–22.
3. Conte PM, Walco GA, Kimura Y. Temperament and stress re-
sponse in children with juvenile primary fibromyalgia syndrome.
Arthritis Rheum 2003;48:2923–30.




If we understand Dr. Ehrlich correctly, he takes
issue with our article identifying subgroups of fibromy-
algia (FM) patients based on the underlying mecha-
nisms, because he 1) feels as though the FM label may
cause more problems than it helps, and 2) is bothered by
litigation and other contentious issues surrounding this
diagnosis.
Before responding to these issues, it strikes us as
odd that we need to do so. All rheumatic diseases are
associated with some of the same underlying issues as
those associated with FM. Most of our current “disease”
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criteria are defined largely upon historic notions of what
constituted an illness, and those constructs have funda-
mental flaws if they are critically examined. However,
although we endeavor to better understand any illness,
these labels and constructs help us understand the
underlying cause of a patient’s symptoms, as well as how
to treat the individual.
In osteoarthritis, for example, if the underlying
“disease” is joint space narrowing and osteophyte for-
mation, then why do 30–50% of patients in the popula-
tion with the most severe forms of this disease (e.g.,
Kellgren/Lawrence grade 3 or 4 changes) have no pain
or symptoms (1,2)? In systemic lupus erythematosus
(SLE), if the “disease” is characterized by immune
complex formation and subsequent tissue damage, then
why don’t indices measuring the extent of disease activ-
ity or the damage correlate well with the symptoms SLE
patients are experiencing (3–5)? When peer-reviewed
scientific articles on the underlying mechanisms of these
disorders are published in Arthritis & Rheumatism, the
authors generally are not asked to address questions
regarding the legitimacy of the underlying diagnosis.
As with these other rheumatic disorders, there is
much we must learn regarding FM. However, just as
with these other disorders, the overwhelming majority of
patients who are given the FM label are helped: this
reduces unnecessary further diagnostic testing and gives
both patients and physicians a construct with which to
help understand the underlying mechanisms and, most
importantly, the most effective treatments. To illustrate
this point, imagine if the American College of Rheuma-
tology criteria for FM had not been established. We
would have nothing to “call” individuals with the second
most common rheumatic disease, and no way of stan-
dardizing studies elucidating the underlying mechanisms
or most effective treatments. Would that really repre-
sent a better state of affairs?
The most unfortunate aspect of this letter, and
editorials and opinion pieces in the same vein, is that
they perpetuate many of the myths and stereotypes
regarding FM that research have shown to be untrue
(6,7). The label of FM does not lead to an increase in the
prevalence of FM, nor does it escalate illness behavior
(8). In many patients with the FM syndrome, psychoso-
cial factors play a role in symptom expression, but
worsen symptoms only in some individuals. In fact, in
our article, psychological factors appeared to make the
underlying FM symptoms better rather than worse, in
20% of patients with FM. Finally, it is true that a small
minority of patients with FM, just as with almost any
other medical disorder, become overwhelmed by the
demands of their illness and predicament and seek
solace by applying for disability or pursuing legal action.
The undersigned authors are just as troubled as Dr.
Ehrlich by these “outliers” who become permanently
disabled or receive large damages, but we differ in how
we choose to respond to the problem.
Daniel J. Clauw, MD
David A. Williams, PhD
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Tumor necrosis factor  blockade as therapy for
sarcoidosis: comment on the article by Ulbricht et al
To the Editor:
We read with great interest the report by Ulbricht and
coworkers about successful treatment with infliximab of a
patient with therapy-resistant systemic sarcoidosis (1). Even
though a previous report by Yee and Pochapin (2) is refer-
enced, the authors go on to state that, “To our knowledge, this
is the first case of successful treatment of typical therapy-
resistant multiorgan sarcoidosis.” We would like to point out to
the readers of Arthritis & Rheumatism that the concept of
anti–tumor necrosis factor  (anti-TNF) therapy for sarcoid-
osis is not new, that depending on the agent used, anti–TNF
therapy has had mixed results, and that this treatment concept
is currently undergoing active further investigation.
As pointed out by Ulbricht et al (1), there is a good
scientific rationale for TNF inhibition in sarcoidosis (3).
Based on this rationale, 4 agents have been tried in sarcoidosis:
pentoxifylline, thalidomide, etanercept, and infliximab. Pen-
toxifylline was the first anti-TNF agent used in sarcoidosis
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(4). This drug inhibits the secretion of TNF by activated
monocytes and alveolar macrophages in vitro (5). To date, the
reported clinical success of pentoxifylline has not been corrob-
orated, but a formal prospective trial is currently ongoing at
the National Institute of Health (http://clinicalstudies.info.nih.
gov/detail/A_99-H-0057.html). Thalidomide, which selectively
suppresses TNF production by enhancing degradation of
TNF messenger RNA, has also been reported to be of benefit
in patients with refractory sarcoidosis (6,7). Recombinant
protein TNF inhibitors designed to neutralize circulating
TNF have recently become available, and etanercept and
infliximab have been used in sarcoidosis. A recently performed
open-label prospective trial of etanercept showed disappoint-
ing results in the treatment of stage II or III progressive
pulmonary sarcoidosis, because the number of early treatment
failures had triggered the early-stop rule of the trial (8).
In contrast, the reported experience with infliximab in
sarcoidosis seems to be more encouraging. Nine cases, includ-
ing the one described by Ulbricht et al, of successful infliximab
use in sarcoidosis have been reported to date (1,2,9–13). The
reported dramatic symptomatic and objective responses are
indeed striking and include the most difficult situations such as
neuro- or cardiac sarcoidosis. In addition, there have been
several presentations at meetings, with published abstracts,
that indicate similarly promising results. Although these re-
ports on infliximab in sarcoidosis are encouraging, the number
of patients with “therapy-resistant” sarcoidosis, who have
failed to respond to infliximab, remains unknown. Therefore,
the indiscriminate use of this agent in steroid-dependent
sarcoidosis should be discouraged, and the results of an
ongoing multicenter prospective randomized trial comparing
infliximab with placebo in patients with chronic steroid-
dependent sarcoidosis (http://www.clinicaltrials.gov/ct/show/
NCT00073437) are eagerly awaited. We hope that results as
promising as those reported by Ulbricht et al will be confirmed
by the formal trial.
The failure of etanercept in pulmonary sarcoidosis
should not lead to skepticism about the use of infliximab in
sarcoidosis. Even though both agents effectively neutralize
TNF, different clinical effects of the 2 agents have been well
documented in Crohn’s disease (14–16). Documented proper-
ties of infliximab that are not shared with etanercept include its
ability to bind to peripheral blood lymphocytes and lamina
propria T cells, and to induce apoptosis of activated lympho-
cytes (17). These properties and possible differences in tissue
bioavailability may explain the observed differences in efficacy
between different anti-TNF agents in granulomatous diseases
such as sarcoidosis.
Augustine S. Lee, MD
James P. Utz, MD
Ulrich Specks, MD
Mayo Clinic and Foundation
Rochester, MN
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We thank Dr. Specks and his colleagues for their
interest in our article. Dr. Specks et al give a sophisticated
summary of the literature concerning treatment concepts in
sarcoidosis. Six articles are cited describing infliximab therapy
in sarcoidosis (1–6), but none of them fulfills all of the criteria
described in our case presentation.
We described a female patient with severe sarcoidosis
involving the lung and liver, who also had arthritis. Various
treatment regimens with azathioprine, methotrexate, cyclo-
phosphamide, and pentoxifylline failed to control the disease.
Infliximab therapy induced radiologic remission of the pulmo-
nary and liver involvement and brisk clinical benefit for
arthritis. Yee and Pochapin (1) presented an “unusual case of
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sarcoidosis, manifested by severe protein-losing enteropathy
and proximal myopathy.” In another 3 case reports cited by
Specks et al (2,4,5), patients with cutaneous, pulmonary,
and/or brain manifestations, but not widespread multiorgan
involvement as in our patient, in whom sarcoidosis was partly
refractory, are described. In an additional 2 case reports of
treatment of sarcoidosis involving several organs, improvement
was observed in only 1 organ (3,6).
We agree with Dr. Specks on the necessity for stan-
dardized clinical trials to study the efficacy of TNF blockade
in sarcoidosis. The indication for infliximab therapy has to be
clearly defined. Should TNF blockade be reserved for
therapy-resistant sarcoidosis? Is there a need for adjuvant
immunosuppression with conventional drugs such as azathio-
prine or methotrexate, or additional TNF blockade with
pentoxifylline or thalidomide? However, for patients such as
the one described by our group, who are vitally threatened by
progressive liver failure, TNF blockade with infliximab is a
promising new treatment modality.
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Variant chronic infantile neurologic, cutaneous,
articular syndrome due to a mutation within the
leucine-rich repeat domain of CIAS1
To the Editor:
The chronic infantile neurologic, cutaneous, articular
syndrome (CINCA syndrome), also called neonatal-onset mul-
tisystem inflamatory disease (MIM no. #607115), is a devas-
tating autoinflammatory disease (1). It is characterized by a
neonatal onset with recurrent fever attacks and skin rash.
Neurologic manifestations can range from headache due to
chronic aseptic meningitis, seizures, and spasticity to psy-
chomotor deterioration. Progressive sensorineural hearing loss
and visual impairment, due to optic papillitis and anterior
uveitis (2), contibute to the long-term disability. Arthropathy
affecting the large joints may lead to contractures. The chronic
persistent inflammatory response may end in secondary amy-
loidosis. Most cases of CINCA syndrome are due to mutations
in the CIAS1 gene (3). Mutations in this gene cause a spectrum
of allelic autoinflammatory disorders (4–8). CINCA syndrome
represents the severe end of the disease spectrum. The CIAS1
gene encodes cryopyrin. This protein consists of an amino
terminal pyrin domain, a central nucleotide-binding oligomer-
ization domain (NOD), and a carboxy-terminal leucine-rich
repeat (LRR) domain. To date, all known disease-causing
mutations in CIAS1 have been found within or close to the
region encoding the NOD domain. Herein we describe a
patient with a predominantly neurologic phenotype and a
novel de novo mutation affecting the LRR domain of CIAS1.
The patient was referred to us at the age of 16. He had
been well until the age of 2 years, when he developed recurrent
pains in the ankles, knees, and back, without visible joint
abnormalities. At age 5 years, he developed malaise, weakness,
and intermittent headaches with morning vomiting. Symptom-
free intervals never lasted longer than 2 weeks. Initially, he had
had a transient erythematous eruption over the cheeks, ears,
and elbows, but this did not recur. He never had any conjunc-
tivitis, oral ulcers, joint swelling, diarrhea, rectal blood loss, or
lymphadenopathy. Fever was notably absent. However, a pro-
gressive sensorineural hearing loss developed, necessitating
the use of hearing aids. Gradually, from the age of 4 years
onward, growth deteriorated, with height dropping from the
fiftieth percentile to below the third percentile for age,
whereas head circumference rose from the seventy-fifth per-
centile to above the ninety-seventh percentile at the age of 16.
Treatment with nonsteroidal antiinflammatory drugs,
5-aminosalicylic acid, and colchicine had been ineffective. Oral
prednisone (0.5–1 mg/kg per day) provided only partial relief.
Physical examination of the patient at the age of 16
years revealed a prominent forehead and delayed pubertal
development (Tanner stage P2G2, testicular volume 6 ml).
Anterior spinal flexion was reduced. The peripheral joints were
not swollen, painful, or inflamed, and although he moved
rather stiffly, passive motion of the arms and legs was not
impaired. Digital clubbing was prominent. Meningism was
absent.
Retinal fluorescent angiography showed papilledema,
with dye leaking from central vessels. Audiography revealed a
bilateral sensorineural hearing loss of 40–70 dB. Findings on
blood tests had been persistently abnormal, with mild micro-
cytic anemia, thrombocytosis, leukocytosis, granulocytosis, and
eosinophilia. Throughout the entire disease course, erythro-
cyte sedimentation rate values ranged from 45 to 92 mm/hour,
and the C-reactive protein level varied between 60 and 140
mg/liter. Immunoglobulins were polyclonally elevated, and the
complement CH50 level was raised. The results of extensive
serologic studies for autoimmune abnormalities had been
consistently negative. The urine contained no cells or protein.
Consecutive computed tomography scans and magnetic reso-
nance imaging of the brain had shown slightly enlarged cere-
brospinal fluid (CSF) spaces, but otherwise no abnormalities.
At the age of 16 years, the patient’s CSF pressure was elevated
(26 cm H2O), as were the CSF protein level (1.31 gm/liter) and
the leukocyte count (175/l; mainly neutrophils, eosinophils,
and monocytes).
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All 9 exons of the CIAS1 gene were amplified using the
polymerase chain reaction as described by Hoffman et al (8).
The amplicons were directly sequenced. We identified an
A2685G transition in exon 6 encoding a Tyr859Cys missense
mutation (TAT-TGT). Tyr859Cys is located in the third of 7
LRRs present in cryopyrin. Neither of the patient’s parents
carried this mutation. Non-paternity was excluded, suggesting
that this is a de novo mutation, although the possibility of
mosaicism in one of the parents cannot be excluded. Analysis
of 50 normal chromosomes did not reveal this alteration. We
therefore conclude that Tyr859Cys is a disease-causing muta-
tion. Disease-causing mutations affecting the LLR domain of
cryopyrin have not been reported before (Infevers database:
http://fmf.igh.cnrs.fr/infevers).
The clinical phenotype in the patient described herein
seems to differ from that of CINCA or Muckle-Wells syn-
drome in that fever, arthritis, and rash have been largely absent
during his disease course. Whether this variant phenotype is
truly due to altered function of the LRR can only be ascer-
tained when additional cases in which the mutation affects the
LRR rather than the NOD are identified. However, mutations
in a closely related gene, NOD2, do give rise to different
phenotypes depending on the affected domain. Mutations
affecting the NOD of NOD2 cause Blau syndrome (MIM no.
#186580), characterized by early-onset granulomatous inflam-
mation of the joints, eyes, skin, and cranial nerves (9), whereas
mutations affecting the LRR domain lead to familial Crohn’s
disease (10), a distinct phenotype of granulomatous inflamma-
tion.
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